31637-97-5 | Etofibrate

Packsize	Purity	Availability	Price	Discounted Price
1mg	98%	in stock	$9.00	$6.00
10mg	98%	in stock	$16.00	$11.00
25mg	98%	in stock	$26.00	$18.00
100mg	98%	in stock	$59.00	$41.00
250mg	98%	in stock	$106.00	$74.00
1g	98%	in stock	$280.00	$196.00

Description

• Catalog Number: AF58974
• Chemical Name: Etofibrate
• CAS Number: 31637-97-5
• Molecular Formula: C18H18ClNO5
• Molecular Weight: 363.7922
• MDL Number: MFCD00865727
• SMILES: Clc1ccc(cc1)OC(C(=O)OCCOC(=O)c1cccnc1)(C)C

Computed Properties

• Complexity: 449
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 25
• Hydrogen Bond Acceptor Count: 6
• Rotatable Bond Count: 9
• XLogP3: 3.5

Literature

• Nutritional and metabolic status of HIV-positive patients with lipodystrophy during one year of follow-up.

  Clinics (Sao Paulo, Brazil) 20110301

• Human health risk assessment of pharmaceuticals in water: issues and challenges ahead.

  International journal of environmental research and public health 20101101

• Methods of chromatographic determination of medicines decreasing the level of cholesterol.

  Acta poloniae pharmaceutica 20100101

• [Efficacy and safety of etofibrate in patients with non-proliferative diabetic retinopathy].

  Klinische Monatsblatter fur Augenheilkunde 20090701

• Etofibrate enhances 123I-LDL-binding in human liver.

  Hellenic journal of nuclear medicine 20090101

• Substituted tertiary phosphine Ru(II) organometallics: catalytic utility on the hydrolysis of etofibrate in pharmaceuticals.

  Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy 20081001

• Peroxisome proliferator activated receptors and lipoprotein metabolism.

  PPAR research 20080101

• Determination of etofibrate, fenofibrate, and atorvastatin in pharmaceutical preparations and plasma using differential pulse polarographic and square wave voltammetric techniques.

  Journal of AOAC International 20080101

• High performance liquid chromatographic determination of etofibrate and its hydrolysis products.

  Journal of pharmaceutical and biomedical analysis 20070104

• Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review.

  International journal of nanomedicine 20060601

• Influence of etofibrate on LDL-subtype distribution in patients with diabetic dyslipoproteinemia.

  Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20030901

• Mass spectrometric monitoring of the degradation and elimination efficiency for hardly eliminable and hardly biodegradable polar compounds by membrane bioreactors.

  Water science and technology : a journal of the International Association on Water Pollution Research 20020101

• Effects of etofibrate upon the metabolism of chylomicron-like emulsions in patients with coronary artery disease.

  Atherosclerosis 20010201

• Etofibrate but not controlled-release niacin decreases LDL cholesterol and lipoprotein (a) in type IIb dyslipidemic subjects.

  Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas 20010201

• Treatment of dyslipoproteinemia in the metabolic syndrome.

  Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20010101

• Studies with etofibrate in the rat. Part I: Effects on glycerol, free fatty acid and triacylglycerol metabolism.

  Biochimica et biophysica acta 19881104

• Mitochondrial myopathy--a result of clofibrate/etofibrate treatment? Case report.

  Acta neuropathologica 19850101